Mattia Carbotti

Dr. Mattia Carbotti

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2015 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MCMattia Carbotti
Mattia Carbotti
RCRosa Coppola
Rosa Coppola
AGAntonio Graziano
Antonio Graziano
MRMaria Verona Rinati
Maria Verona Rinati
FPFrancesco Luigi Paolilli
Francesco Luigi Paolilli
VPVincenzo Panasiti
Vincenzo Panasiti

1 January 2018 in International Journal of Immunopathology and Pharmacology
Verified
Journal Article
Open access
EPEnzo Palese
Enzo Palese
MNMaurizio Nudo
Maurizio Nudo
GZGrazia Zino
Grazia Zino
VDValeria Devirgiliis
Valeria Devirgiliis
MCMattia Carbotti
Mattia Carbotti
VPVincenzo Panasiti
Vincenzo Panasiti
Candidiasis is a fungal infection caused by yeasts that belong to the genus Candida. There are over 20 species of Candida yeasts that can cause infection in humans, the most common of which is Candida albicans. Candida yeasts normally reside in the intestinal tract and can be found on mucous membranes and skin without causing infection. However, under immunocompromised conditions, Candida can cause significant infections in susceptible patients. Herein, we report a peculiar presentation of a C. albicans cutaneous infection in an immunocompetent young subject. This case widens our knowledge on the C. albicans infections both in terms of host susceptibility and cutaneous manifestations.

14 March 2014 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
RCR. Coppola
R. Coppola
SZS. Zanframundo
S. Zanframundo
MRM. Verona Rinati
M. Verona Rinati
MCMattia Carbotti
Mattia Carbotti
AGA. Graziano
A. Graziano
VPV. Panasiti
V. Panasiti

6 May 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
GAGabriele Arcari
Gabriele Arcari
FNFederica Novazzi
Federica Novazzi
LCLorenzo Colombini
Lorenzo Colombini
FFFrancesca Drago Ferrante
Francesca Drago Ferrante
SBSara Boutahar
Sara Boutahar
NMNicasio Mancini
Nicasio Mancini
Streptococcus pyogenes (Group A Streptococcus ; GAS) is a pathogen of global significance. In the pre-antibiotic era, GAS was a major cause of childhood morbidity and mortality, but its spread rapidly declined until the mid-2010s. The continuing increase in GAS infections, associated with the expansion of the M1 UK lineage, was observed first in the United Kingdom (UK) and, later, globally. Here, we endeavor to assess the various determinants underlying the post-pandemic GAS upsurge, with a focus on microbial genomic features. We performed an epidemiological analysis of all laboratory-confirmed GAS infections identified between June 2018 and June 2024 at a tertiary University Hospital located in Northern Italy, dividing them into three levels of severity: mild, moderate, and invasive GAS infections. A subset of 34 representative GAS isolates identified in the post-pandemic period were subjected to short- and long-read whole genome sequencing (WGS). Of the 531 GAS cases analyzed during this period, the majority (415, 78.2%) occurred in the last two years. This increase in GAS cases correlated with a significant shift in infection severity: among the 118 GAS cases identified in the June 2018–May 2022 period, only one resulted in an invasive infection (1/118, 0.8%). In contrast, among the 531 GAS cases identified in the June 2022–May 2024 period, 32 caused invasive infections (32/531, 7.9%). WGS of 34 isolates (including 15 invasive isolates) identified 11 different emm types, the most frequent being emm 1 (9 isolates) followed by emm 12 (7 isolates), then emm 89 and emm 28 (4 isolates each). Among the emm 1 isolates, the M1 UK sublineage was the most represented (8 out of 9 isolates), with the remaining “singleton” belonging to the M1 13SNP sublineage. IMPORTANCE: Streptococcus pyogenes (GAS) is a narrow-spectrum pathogen, circulating only in humans. Following the loosening of various public health measures implemented to face the challenge of the COVID-19 pandemic, a significant rise in GAS cases has been observed. Our study revealed a significant rise in GAS cases, particularly invasive infections, over the last two years. Genomic analysis identified multiple sequence types, including isolates belonging to an emerging lineage named M1 UK . These findings underscore the importance of ongoing surveillance and genomic monitoring of GAS infections, especially considering their rising incidence and severity. Public health strategies should consider not only microbe-associated aspects but also host-associated and external factors to effectively address this resurgence and prevent future outbreaks.

1 June 2015 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
RCRosa Coppola
Rosa Coppola
MCMattia Carbotti
Mattia Carbotti
SZSalvatore Zanframundo
Salvatore Zanframundo
MRMaria Verona Rinati
Maria Verona Rinati
AGAntonio Graziano
Antonio Graziano
VPVincenzo Panasiti
Vincenzo Panasiti

29 August 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MCMattia Carbotti
Mattia Carbotti
RCRosa Coppola
Rosa Coppola
SZSalvatore Zanframundo
Salvatore Zanframundo
VDValeria Devirgiliis
Valeria Devirgiliis
VPVincenzo Panasiti
Vincenzo Panasiti
Actinic keratosis (AK) is a common skin lesion in adults which usually occurs on chronically photoexposed areas and considered as a precancerous lesion or a superficial squamous-cell carcinoma. Many classifications have been proposed and its diagnosis is generally clinical but, sometimes, its wide variety of presentations can make diagnosis difficult, even among expert observers. The malignant potential of AKs imposes an early diagnosis and treatment in order to reduce morbidity and mortality, and, for the characterization of photodamaged skin, noninvasive diagnostic techniques, such as dermoscopy, have proved to be useful, while multiple therapeutic strategies, lesion-directed versus field-directed therapies, are available for the treatment of AKs. In this study, we evaluated the efficacy of ingenol mebutate for the treatment of AKs, with a particular focus on patients’ compliance, correlating it to clinical and dermoscopic grading, pre- and posttreatment, of these lesions. Fifty-two enrolled patients with AKs received treatment with ingenol mebutate gel (0.015% for face and scalp; 0.05% for trunk and extremities) and multiple dermatological evaluations. End points of the study were complete and partial clearance of clinically visible AKs on day 90. All acquired data were recorded and statistical analyses were performed. Univariate and multivariate analyses were used to identify possible predictive factors. We retrospectively analyzed patient-related and lesion-related factors to identify which variables, among age, gender, lesion site, pain, LSR score, and pretreatment clinical and dermoscopic grading, could independently predict the response to ingenol mebutate treatment. Our findings showed that pretreatment dermoscopic grade II represents an independent predictive factor of the efficacy of ingenol mebutate therapy (OR=14.78, 95% CI: 1.83–119.59, P=0.012) and that response rates differ on the basis of the treated anatomical sites (OR=0.16, 95% CI: 0.03–0.85, P=0.031). Data from this study provide evidence that ingenol mebutate gel is an effective treatment for AK, with relative ease of use, short exposure, and rapid resolution of local reactions, benefits contributing to high adherence of this therapy. Moreover, dermoscopic analysis of skin lesions offers more information than clinical evaluation alone and can be helpful in identifying different groups of AKs, thus selecting the adequate therapeutic choice.